

# **Fourth Quarter and Full-Year 2021 Financial Results and Business Update**

April 28, 2022

Franz-Werner Haas

Business Update

Chief Executive Officer

Klaus Edvardsen

Program Update

Chief Development Officer

Pierre Kemula

Financial Update

Chief Financial Officer



# Forward-Looking Statements

The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements.

Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov).



## Prophylactic Vaccines: Executing on infectious disease program

In collaboration with GSK

- Initiated Phase 1 dose-escalation study for **COVID-19** with unmodified candidate, **CV2CoV**, in the U.S.
- Fully recruited Phase 1 dose-escalation study for **influenza** with first multivalent candidate, **CVSQIV**, good tolerability profile confirmed
- Technology expansion into **bivalent approach for COVID-19** with preclinical study for **combined Beta/Delta** candidate



## Oncology: Building a cancer vaccines portfolio

- **Expand unique mRNA approach** based on recent technology platform advances, particularly second-generation mRNA backbone
- **Gain momentum** by validating broad mRNA technology approach, accessing novel antigens and adding complementary platform technologies



## The RNA Printer®

CureVac's solution for automated manufacturing of GMP-grade RNA vaccines and therapeutics

- Launched **CureVac Printer GmbH** with experienced management to accelerate development of The RNA Printer®
- Enable broad **access to RNA technology** to accelerate transfer of innovative mRNA products from **lab to clinic**



## Pandemic Preparedness Contract

Consortium with GSK


- 5-year contract with **German government** reserves domestic mRNA **manufacturing capacity** in case of public health crisis
- Committing to rapid availability of **80 million doses** of mRNA-based vaccine developed by **CureVac and GSK**




## Financial Update

- Cash position of **€811.5 million** as of December 31, 2021

# One of the Largest and Most Diverse mRNA Patent Portfolios with >1000 issued Patents








# Independent Analysis of Strongest Patents Related to COVID-19 Vaccines\*



## Top 20 Companies

■ Patent Asset Index™  
■ Portfolio size

# CureVac Pipeline: A Diversified Portfolio

AREA	PROGRAM	CANDIDATE	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
PROPHYLACTIC VACCINES	1 <sup>st</sup> -Gen COVID-19 Program	1 <sup>st</sup> -Gen candidate: CVnCoV <sup>1)</sup>	<div></div>	<div></div>	<div></div>	<div></div>
	2 <sup>nd</sup> -Gen COVID-19 Program 	2 <sup>nd</sup> -Gen candidate: <b>CV2CoV</b>	<div></div>	<div></div>		
		Further 2 <sup>nd</sup> -Gen candidates	<div></div>			
	Infectious Disease Program 	Influenza: <b>CVSQIV</b>	<div></div>	<div></div>		
		Four undisclosed targets	<div></div>			
	Rabies	CV7202	<div></div>	<div></div>		
	Diverse Projects 	Rota, malaria, universal influenza	<div></div>			
ONCOLOGY	Solid tumors <sup>2)</sup>	CV8102	<div></div>	<div></div>		
	Shared neo-antigen	-	<div></div>			
	Tumor Associated Antigens	-	<div></div>			
MOLECULAR THERAPY	Cas9 gene-editing 	CRISPR Therapeutics collaboration	<div></div>			
	Liver Diseases	REBIRTH-Research Center collaboration	<div></div>			
	Ocular Diseases	Sheppens Eye Research Institute collaboration	<div></div>			
	Lung Diseases	Yale collaboration	<div></div>			
	Therapeutic Antibodies 	Genmab collaboration	<div></div>			

## Phase 1: CV2COV – COVID-19 CANDIDATE

- **Preclinically promising** candidate
- **Non-chemically modified** second-generation construct
- Validating backbone for flexible **variant adaptation**
- Dose-escalation study in the **U.S.**
  - **2-dose** booster study
  - Up to **210** participants **to be recruited**

### DOSE ESCALATION



## Phase 1: CVSQIV – INFLUENZA CANDIDATE

- Differentiated **multivalent** vaccine candidate
- **Non-chemically modified** second-generation construct
- Addressing **four different influenza strains**
- Dose-escalation study in **Panama**
  - **1-dose** booster study
  - **Fully recruited** with **240** participants


### DOSE ESCALATION




# CVSQIV Displaying a Benign Reactogenicity Profile Across all Dose Groups\*



## Systemic symptoms



## Local symptoms



Grade 0

Grade 1

Grade 2

Grade 3

Older population:


Younger population:

At or above the age of **65** (n=120)


**18 to 55** years of age (n=120)

# Expanding Multivalent Technology in COVID-19 in Preclinical Study\*


Strong neutralizing antibodies **against both variants** at half dose per mRNA\*\*




Balanced immune response with robust **induction of T cells**



High **protective efficiency**, reducing viral load in upper respiratory tract\*\*



# Expanding Multivalent Technology in COVID-19 in Preclinical Study\*



- In rats neutralizing antibody titers against **Omicron** BA.1 notably **diminished by 3-9-fold** for all tested vaccine candidates but the bivalent vaccine
- **Adding Beta** to the Delta variant in the bivalent vaccine resulted in **2-fold higher VNTs** against **Omicron** BA.1 than those induced against the Delta variant
- Multivalent mRNA vaccines encoding variants with unrelated lineages may **increase the breadth** of immune responses and hence induce **heterologous protection**

## INDUCTION OF T CELL RESPONSES

### APPLY CURRENT mRNA TECHNOLOGY ADVANTAGES

- Taking advantage of our **technology advances**
- Validating current **T cell induction** mechanisms
- Optimizing current **technology approaches**

### BUILD PIPELINE OF CANCER VACCINE CANDIDATES

- Accessing **novel classes** of antigens
- Exploit **synergies** with other cancer treatments
- Leveraging agility of **The RNA Printer®**

### ADD HIGHLY COMPLEMENTARY PLATFORMS

- Extended **antigen discovery** strategies
- New technologies for **immuno-stimulation**
- Approaches for vaccine **design optimization**

## Focus on Cancer Vaccines

# Accelerating Development of The RNA Printer® with Dedicated Ecosystem



## ESTABLISHING THE CUREVAC RNA PRINTER GMBH

- Dedicated infrastructure and experienced management
- Establish system as automated end-to-end manufacturing solution



Fully owned  
CureVac subsidiary

## TRANSLATING SCIENCE INTO INNOVATIVE PRODUCTS

- Enable broad access to mRNA technology
- Increase speed of advancing mRNA products from lab to clinic



Including pandemic vaccines or  
personalized cancer therapies


## ENABLING mRNA ACCESS INTERNALLY AND EXTERNALLY

- Enabling work with external partners and customers
- Support the CureVac pipeline with a focus on oncology



Pursuing different  
collaboration models

# Pandemic Preparedness Contract with German Government until 2029



# Cash and Condensed Consolidated P&L Data

	December 31, 2021	December 31, 2020
(in € millions)		
<b>Cash and Cash Equivalents</b>	<b>811.5</b>	<b>1,322.6</b>

	Three months ended December 31,		Twelve Month ended December 31,	
	2021	2020	2021	2020
(in € millions)			Summary of Audited Full Year Accounts	
Revenue	41.2	6.0	103.0	48.9
Cost of Sales, Operating Expenses & Other Operating Income	-46.7	-52.6	-515.3	-158.7
<b>Operating Result</b>	<b>-5.5</b>	<b>-46.6</b>	<b>-412.3</b>	<b>-109.8</b>
Financial Result	1.0	-10.7	-0.2	-20.0
<b>Pre-Tax Loss</b>	<b>-4.5</b>	<b>-57.3</b>	<b>-412.5</b>	<b>-129.8</b>



Progressing solid **product** development pipeline, versatile **technology** platform and robust **manufacturing**



Broad and diverse IP portfolio protecting our **competitive positioning** as a **central RNA player**



Executing clinical development plan for **COVID-19** and **influenza** with **multivalent** and **modified** mRNA approaches



Expanding next growth driver in oncology using novel antigens for **T cell mediated immune responses** supported by **The RNA Printer®**



**Strong cash position** of €811.5 million for executing on programs and **priorities in 2022**





**Thank you for your  
attention**

CureVac  
[www.curevac.com](http://www.curevac.com)